Newsletters - Page

Is your Biomarker Strategy Up-to-Date?

Research on neurological biomarkers is a very dynamic field. The recent FDA approval of a diagnostic test measuring the Amyloid-beta 1-42 / 1-40 ratio in CSF for Alzheimer's disease, or the breakthrough device status granted to a blood test measuring NfL levels in Multiple Sclerosis are a clear illustration of this trend.

At Active Biomarkers, we have implemented methods to detect neurological biomarkers in both CSF AND Blood matrices, using ultrasensitive immunoassays when required.

Learn more here

Developing a new analytical method is just like crossing the Ocean: the Departure and Arrival are clearly marked but the journey is unknown and might change according to the weather forecast.

A TRUSTED PARTNER to stay the course is key to SUCCESS!

Lear how we can help you reach your destination

Why is Receptor Occupancy Assay so important in the development of your biologics?

Receptor Occupancy Assay (ROA) by flow cytometry for quantitative assessment of the binding of a therapeutic agent to its cell-surface target, is valuable at each step of drug development for:

› Documenting the Mechanism of Action
› Demonstrating Target Engagement
› Correlating engagement to efficacy in vivo
› Building PK/PD models
› Anticipating potential safety issues 
› And eventually establishing optimal dosing and administration schedule

Here's what you need to consider for a successful ROA

For clinical monitoring, patient stratification, documenting target engagement, leverage our ULTRASENSTITIVE and MULTIPLEX assays.

Click here to learn more

Wanted or unwanted? Check the impact of your vaccine candidate on patients' immune system thanks to our comprehensive bioanalytical toolbox.

Fast and flexible! Translate your precious and limited samples into reliable data with the Ella™ multiplex system. Just ACT!